Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 19Unknown 10Recruiting 10Terminated 4Withdrawn 2Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 4INDUSTRY 4NIH 2NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Neoplasm Metastasis 1Endometrial Cancer Recurrent 1Breast Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 240Radiotherapy 216Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Rituximab 141Capecitabine 141pembrolizumab 139Oxaliplatin 124Nivolumab 124Dexamethasone 122Fluorouracil 113fludarabine 103Radiosurgery 101Doxorubicin 99fludarabine phosphate 96Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 91Magnetic Resonance Spectroscopy 90Radiation 89Leucovorin 88Filgrastim 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × OTHER × Crizotinib × Clear all
NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

National Cheng-Kung University Hospital

Phase 2 Terminated
40 enrolled
Gynecologic

Endometrial Cancer Recurrent

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Wake Forest University Health Sciences

Phase 2 Terminated
8 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Terminated
178 enrolled

Advanced Cancers

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated
3 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡